Onconetix Inc
For the period ended Mar 31, 2024. Filed May 20, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 20, 2024
ONCO$3.47-3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(11,118,572) | $(2,846,644) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Impairment of goodwill | 5,192,000 | — |
| Impairment of ENTADFI assets | 2,293,576 | — |
| Amortization of debt discounts | 182,928 | — |
| Amortization of debt discount – related party | 174,774 | — |
| Depreciation and amortization | 206,700 | 1,698 |
| Change in fair value of subscription agreement liability – related party | (226,400) | — |
| Net periodic pension benefit | (58,404) | — |
| Stock-based compensation | 52,650 | 185,578 |
| Interest accrued on note payable – related party | 50,000 | — |
| Change in fair value of contingent warrant liability | — | (1,615) |
| Deferred tax benefit | (121,567) | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (116,763) | — |
| Inventories | (36,974) | — |
| Prepaid expenses and other current assets | (419,530) | (321,961) |
| Other noncurrent assets | (7,750) | 23,117 |
| Accounts payable | (1,017,428) | (1,237,493) |
| Accrued expenses | (261,303) | (214,311) |
| Net cash used in operating activities | (5,232,063) | (4,411,631) |
| Cash flows from investing activities | ||
| Net advances to related parties | — | (34,452) |
| Purchases of property and equipment | (4,578) | (1,819) |
| Net cash used in investing activities | (4,578) | (36,271) |
| Cash flows from financing activities | ||
| Proceeds from issuance of note payable – related party | 5,000,000 | — |
| Proceeds from issuance of note payable | 678,550 | — |
| Payment of financing costs | (400,000) | — |
| Principal payment of note payable | (73,457) | — |
| Payment of deferred offering costs | (15,500) | |
| Purchase of treasury shares | — | (33,454) |
| Net cash provided by (used in) financing activities | 5,205,093 | (48,954) |
| Effect of exchange rate changes on cash | (58,917) | — |
| Net decrease in cash | (90,465) | (4,496,856) |
| Cash, beginning of period | 4,554,335 | 25,752,659 |
| Cash, end of period | $4,463,870 | $21,255,803 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $4,405 | $— |
| Noncash investing and financing activities: | ||
| Deferred offering costs included in accounts payable and accrued expenses | $— | $339,593 |
| Deferred offering costs previously included in prepaid expenses | $— | $(11,020) |
| Exercise of pre-funded warrants | $— | $7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.